Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.

Updates in surgery - 1 Mar 2015

Martellucci Jacopo, Alemanno Giovanni, Castiglione Francesca, Bergamini Carlo, Valeri Andrea

Abstract excerpt

Individual patient response to neoadjuvant treatment is variable and reproducible biomarkers of response are needed. The role of the V-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) in rectal cancer remains equivocal. The aim of the current study was to evaluate the effect of KRAS mutation on outcomes following neoadjuvant chemoradiation therapy (CRT) for rectal cancer. A total of 76 stage II-III rectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonoscopy
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endosonography

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 25702261
DOI: 10.1007/s13304-015-0281-8

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.PMID 25702261Read ↗

KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

The effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery.Semantic proximity Read ↗

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis.Semantic proximity Read ↗

Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal Cancer Patients Undergoing Neoadjuvant Treatment.Semantic proximity Read ↗

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.